Daehan Nupharm Co.,Ltd.
Financials
Valuation Metrics
Daehan Nupharm Co.,Ltd.'s Market Cap is ₩798B. At end of 2025 it was ₩943B. Ranked #1422 of 2,421 in KR market (top 59%), #812 of 1,640 on KOSDAQ (top 50%), #153 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 66%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 79.81B KRW | KR#1,422/2,421 Sec#153/231 |
| Revenue | 211.48B KRW | KR#996/2,421 Sec#56/231 |
| Net Income | 23.93B KRW | KR#639/2,421 Sec#40/231 |
| Total Assets | 281.20B KRW | KR#1,072/2,421 Sec#72/231 |
| Net Assets | 148.94B KRW | KR#1,138/2,421 Sec#79/231 |
| Employees | 397 | KR#613/2,421 Sec#52/231 |
| Value | ||
| P/E | 3.33x | KR#181/2,421 Sec#7/231 |
| P/B | 0.54x | KR#866/2,421 Sec#43/231 |
| PEG | 0.02x | KR#218/2,421 Sec#12/231 |
| P/S | 0.38x | KR#724/2,421 Sec#22/231 |
| EV/EBITDA | 28.41x | KR#1,171/2,421 Sec#70/231 |
| FCF Yield | -43.28% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROE | 16.07% | KR#277/2,421 Sec#17/231 |
| ROA | 8.51% | KR#392/2,421 Sec#28/231 |
| Op. Margin | 4.59% | KR#1,011/2,421 Sec#73/231 |
| Revenue Growth | 4.95% | KR#1,201/2,421 Sec#117/231 |
| Earnings Growth | 133.79% | KR#330/2,421 Sec#20/231 |
| Financial Health | ||
| Debt Ratio | 88.80% | KR#1,448/2,421 Sec#169/231 |
| Total Debt | 211.23B KRW | KR#501/2,421 Sec#25/231 |
| FCF | -34.54B KRW | KR#2,017/2,421 Sec#196/231 |
| Cash | 15.25B KRW | KR#1,412/2,421 Sec#110/231 |
| Current Ratio | 1.76x | KR#994/2,421 Sec#111/231 |
| Net Debt/EBITDA | 20.19x | KR#1,375/2,421 Sec#99/231 |
| Dividend | ||
| Div. Yield | 1.80% | KR#922/2,421 Sec#47/231 |
| Div. Growth | 0.00% | KR—/2,421 Sec—/231 |
| Performance | ||
| 1Y Return | -21.02% | KR#1,287/2,421 Sec#90/231 |
| 1M Return | -2.80% | KR#1,566/2,421 Sec#126/231 |
| From 52W High | -29.62% | KR#519/2,421 Sec#31/231 |
| 1Y MDD | -32.22% | KR#324/2,421 Sec#24/231 |
| Trading | ||
| Volume | 6,501 shares | KR#2,056/2,421 Sec#197/231 |
| Trading Value | 36.2M KRW | KR#1,949/2,421 Sec#199/231 |
| Foreign Own. | 0.26% | KR#2,264/2,421 Sec#218/231 |
| Per Share | ||
| EPS | 1,667 KRW | KR#506/2,421 Sec#33/231 |
| BPS | 10,376 KRW | KR#972/2,421 Sec#68/231 |
Company Info
Established in 1984 and listed on KOSDAQ in 2002, Daehan Newpharm is a pharmaceutical company headquartered in Hwaseong-si, Gyeonggi-do. It focuses on specialty pharmaceuticals for metabolic diseases like hypertension and diabetes, as well as digestive ulcer treatments, while strengthening non-reimbursable products such as obesity treatments, vitamins, and immune enhancers. The company diversifies into animal pharmaceuticals, developing pet products and farm environment improvers, and expands its bio business into stem cell-based anti-aging agents and cell therapies.